CNS
-
Brain penetrating JAK1/TYK2 inhibitors for inflammation, autoimmune and CNS diseases
If you are looking for brain-penetrating JAK1/TYK2 inhibitors, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
US biotech companies are seeking TYK2 products that can penetrate the BBB and have potential CNS indications
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
-
美国上市公司寻找能够穿透BBB而有CNS适应症潜力的TYK2产品
如果贵公司对这个机会感兴趣，请速速联系药时代BD团队！
-
【快讯】6.5亿美元！GSK与Flagship孵化的Vesalius达成多靶点战略联盟，为帕金森病患者开发突破性疗法
药时代热烈祝贺GSK和Vesalius Therapeutics！
-
GSK and Vesalius Enter Multi-Target Strategic Alliance to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Congratulations to GSK and Vesalius Therapeutics!
-
AbbVie’s stock price plummets!
Drug discovery and development is not easy at all. We pay high respect to these heroes
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
-
【诚聘付费专家】 电话咨询主题：抑郁症新药研发的竞争格局与潜在机遇
我们将严格保密，敬请放心！衷心感谢！
-
科睿唯安交易并购报告 | 2020年第二季度行业纵览与解析
原文始发于微信公众号（科睿唯安生命科学与制药）：科睿唯安交易并购报告 | 2020年第二季度行业纵览与解析 ⬆️欢迎参加2020中国新药CMC高峰论坛！ 交易引领生物制药行业发展 …
